Application of new vaccine technologies for the control of transboundary diseases.
Vaccines have played an important role in the control of diseases of livestock and poultry, including Transboundary Diseases. In the future, vaccines will play a greater role in controlling these diseases. Historically, inactivated whole viruses in various adjuvant systems have been used and will continue to be used in the near future. For the future, emerging technologies will allow targeted use of only the protective antigens of the pathogen and will provide the opportunity for differentiating between vaccinated and field-exposed animals. Furthermore, the expression of cytokines by vaccines will afford earlier or greater enhancement of protection than can be achieved by the protective response elicited by the antigenic epitopes of the pathogen alone. Avian influenza (AI) is a good case for studying future trends in vaccine design and use. Inactivated AI virus (AIV) vaccines will continue as the primary vaccines used over the next 10 years. These vaccines will use homologous haemagglutinin sub-types, either from the use of field strains or the generation of new strains through the use of infectious clones produced in the laboratory. The latter will allow creation of high growth reassortants, which will provide consistent high yields of antigen and result in potent vaccines. New viral and bacterial vectors with inserts of AIV haemagglutinin gene will be developed and potentially used in the field. Such new vectors will include herpesvirus-turkey, infectious laryngotracheitis virus, adenoviruses, various types of paramyxoviruses and Salmonella sp. In addition, there is a theoretical possibility of gene-deleted mutants that would allow the use of live AIV vaccines, but the application of such vaccines has inherent dangers for gene reassortment with field viruses in the generation of disease-causing strains. Subunit haemagglutinin protein and DNA haemagglutinin gene vaccines are possible, but with current technologies, the cost is prohibitive. In the future, effective AI vaccines must prevent clinical signs and death, increase resistance of the host to infection, decrease the rate of replication and shedding of a challenge or field virus and provide uniform protection following single immunization. Mass application technologies of new virus or bacterial vector systems will provide economic incentives for adoption over current labour-intensive manual individual bird injection methods used with today's AI vaccines.
Swayne
D E
DE
Southeast Poultry Research Laboratory, Agricultural Research Service, U.S. Department of Agriculture, Athens, GA 30605, USA. dswayne@seprl.usda.gov
D000818:Animals; D001709:Biotechnology; D003140:Communicable Disease Control / Q000379:methods*; D009980:Influenza A virus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000235:genetics / Q000276:immunology*; D005585:Influenza in Birds / Q000276:immunology / Q000517:prevention & control*; D011200:Poultry; D014611:Vaccination / Q000379:methods / Q000592:standards / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D014765:Viral Vaccines